patisiran

FDA
Biotech

FDA delays decision on inotersen, handing lead to Alnylam

Akcea suffered the setback after the FDA asked for more time to review its response to requests for information on the rare disease antisense drug.
Nick Paul Taylor May 4, 2018 8:28am
John Maraganore

Alnylam builds out case for patisiran, showing drop in mortality

Apr 24, 2018 7:48am
Sanofi offices

Alnylam retools Sanofi deal to take full control of patisiran

Jan 8, 2018 6:52am
stop sign

Alnylam halts fitusiran trials after patient with hemophilia dies

Sep 7, 2017 11:00am